Please login to the form below

Not currently logged in
Email:
Password:

breast cancer

This page shows the latest breast cancer news and features for those working in and with pharma, biotech and healthcare.

Gilead agrees $21bn buyout of Immunomedics

Gilead agrees $21bn buyout of Immunomedics

treatment of metastatic triple-negative breast cancer (mTNBC). ... The ADC is also being studied in an ongoing phase 3 trial in third line HR+/HER2-positive breast cancer, and a registrational phase 2 study in bladder cancer.

Latest news

More from news
Approximately 112 fully matching, plus 704 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    keep it inhibited – and which also run the risk of cancer cells acquiring resistance by developing receptor mutations. ... this way. AstraZeneca’s injectable drug Faslodex (fulvestrant) for breast cancer has been approved since 2002, and acts by

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    HER2 positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. ... treatment pathway in HER2-positive breast cancer as quickly as possible, challenging Roche’s duo of Herceptin and Perjeta (pertuzumab

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    Sometimes prices fall so low manufacturers lose interest. For example, a shortage of the cancer drug vincristine occurred recently when Teva stopped making it and then subsequently the sole remaining manufacturer, ... First-to-market generics included

More from intelligence
Approximately 1 fully matching, plus 70 partially matching documents found.

Latest appointments

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    cancer programme, associate director for strategic relations for the Duke Cancer Institute among other roles. ... cancer research, especially metastatic breast cancer, where she has led programmes that resulted in numerous ground-breaking regulatory

  • Ipsen boosts specialty care and R&D leadership teams Ipsen boosts specialty care and R&D leadership teams

    Prior to this, he served as executive director and breast cancer lead for US oncology medical affairs, and held a number of medical affairs oncology positions at Novartis and Bayer.

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

  • Agendia appoints chairman of medical advisory board Agendia appoints chairman of medical advisory board

    Dr Hortobagyi brings over 35 years of experience in clinical and translational research of breast cancer and work as a breast medical oncologist to the molecular cancer diagnostics company. ... He currently also serves as a professor and chair Emeritus

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 24 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics